Enanta Pharmaceuticals, Inc. (FRA:9EP)

Market Cap	315.08M +217.3%
Revenue (ttm)	55.68M -3.4%
Net Income	-69.79M
EPS	-3.27
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	8
Open	10.70
Previous Close	10.60
Day's Range	10.50 - 10.70
52-Week Range	3.62 - 14.20
Beta	n/a
RSI	41.67
Earnings Date	Feb 9, 2026

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company’s product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the marke...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1995
• Employees: 120
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 9EP

Financial Performance

In fiscal year 2025, Enanta Pharmaceuticals's revenue was $65.32 million, a decrease of -3.42% compared to the previous year's $67.64 million. Losses were -$81.89 million, -29.43% less than in 2024.

Financial numbers in USD